Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Developing a surgical infection treatment to reduce amputations, healing times and hospital stays for diabetic foot patients

Project description

Innovative device for diabetic foot infections

Deep tissue and bone infections affect millions of Europeans every year. Immunosuppressed patients are particularly vulnerable as 20 % of diabetic foot infections lead to amputations. Treatment requires multiple surgeries, long hospitalisation and long-term antibiotics. Current treatment modalities only treat the surface of the wound or use mechanical forces to treat it below the surface. These treatments are often ineffective. The EU-funded XTremedy Medical project has developed a pulsed field ablation (PFA) system that is a surgical device delivering electrical signals through the wound. The device treats the surface and below to annihilate any residual infection. The technology is non-thermal and preserves wound integrity during treatment, reducing the need for surgery as well as healing time and hospital stay.

Objective

XTremedy Medical is a surgical ablation company founded in 2018 to commercialize technology treating deep wound infections, including Diabetic Foot Infections (DFI). Our pulsed field ablation (PFA) system is the first to deliver electrical currents non-invasively to achieve superior clinical outcomes including faster cure of infections, reduced surgeries and shorter hospital stays.
The Problem:
Deep tissue and bone infections are life threatening infections that affect a millions of Europeans every year. Immunosuppressed patients are particularly vulnerable, with Diabetic Foot Ulcer Infections a leading cause of amputations in Europe. These patients are incredibly difficult to treat, requiring multiple surgeries, lengthy hospital stays and long-term antibiotics. In 20% of patients, an amputation is required to control the infection. Surgical intervention to remove infected tissue is the cornerstone of treatment but surgeons must balance removing infected material whilst preserving healthy tissue required for healing.
Treatment Landscape:
Current treatment modalities either only treat the surface of the wound or use mechanical forces to treat below the surface. Surface treatments fail as they leave infection below the wound bed untreated. Mechanical devices can cause more severe infections by damaging the integrity of the wound bed and propelling the infection deeper. As a result, these treatments are often ineffective, with 50% of patients requiring additional surgeries.
XTremedy Solution:
XTremedy Medical have developed a surgical device that delivers electrical signals through the wound. This device treats both the surface and below to zap any residual infection. The technology is non-thermal and preserves the integrity of the wound during treatment, helping reduce the time required for healing. Patients benefit from reduced surgeries, shortened hospital stays and antibiotic durations following surgery.

Coordinator

XTREMEDY MEDICAL LIMITED
Net EU contribution
€ 75 000,00
Address
TRANSLATIONAL MEDICAL DEVICE LAB, 2ND FLOOR LAMBE TRANSLATIONAL RESEARCH FACILITY, UNIVERSITY COLLEGE HOSPITAL GALWAY, CO. GALWAY
H91ERW1 GALWAY
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Northern and Western West
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data